The Library
Combination of everolimus with sorafenib for solid renal tumors in Tsc2+/− Mmce Is superior to everolimus alone
Tools
Tools
Tools
Yang, Jian, Samsel, Paulina A., Narov, Kalin, Jones, Ashley, Gallacher, Daniel C., Gallacher, John, Sampson, Julian R. and Shen, Ming Hong (2017) Combination of everolimus with sorafenib for solid renal tumors in Tsc2+/− Mmce Is superior to everolimus alone. Neoplasia, 19 (2). pp. 112-120. doi:10.1016/j.neo.2016.12.008
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1016/j.neo.2016.12.008
Abstract
Tuberous sclerosis (TSC) is an inherited tumor syndrome caused by mutations in TSC1 or TSC2 that lead to aberrant activation of mTOR and development of tumors in multiple organs including the kidneys. The mTOR inhibitors rapamycin and everolimus (rapalogs) have demonstrated clinical efficacy in treating TSC-associated tumors including renal angiomyolipomas. However, tumor responses are usually only partial, and regrowth occurs after drug withdrawal. TSC-associated tumors are highly vascular, and TSC patients with renal angiomyolipomas have elevated levels of circulating vascular endothelial growth factor (VEGF) A and VEGFD. Sorafenib inhibits multiple kinases including VEGF receptors and has been used to treat metastatic epithelioid angiomyolipoma in one case, but formal trials have not been undertaken. In this study, we investigated tumor angiogenesis and the therapeutic efficacy of everolimus in combination with sorafenib for renal tumors in Tsc2+/− mice. We found that these tumors exhibited remarkably variable angiogenesis despite consistent aberrant activation of mTOR and increased expression of HIF1α and VEGFA. Treatment of 11-month-old Tsc2+/− mice for 2 months with a combination of everolimus and sorafenib significantly reduced the number and size of solid renal tumors, whereas everolimus or sorafenib alone did not. These results suggest that inhibition of mTOR and multiple kinases including VEGF receptors using combination therapy could hold promise for the treatment of TSC-associated tumors that have responded inadequately to a rapalog alone.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||
| Journal or Publication Title: | Neoplasia | ||||||||
| Publisher: | Elsevier | ||||||||
| ISSN: | 1476-5586 | ||||||||
| Official Date: | February 2017 | ||||||||
| Dates: |
|
||||||||
| Volume: | 19 | ||||||||
| Number: | 2 | ||||||||
| Page Range: | pp. 112-120 | ||||||||
| DOI: | 10.1016/j.neo.2016.12.008 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Open Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
